The United Laboratories Intl. Hldgs (3933)
United Laboratories International Holdings Ltd. is an investment company engages in the manufacture and sale of medicines, and the bulk and intermediate products used to produce finished goods. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment offers two major products, such as T-Octylammonium Clavulanate and 6-APA. The Bulk Medicine segment includes amoxicillin and insulin. The Finished Products segment includes the sale of antibiotics and non-antibiotics finished products, and capsule casings including Semi-synthetic penicillins antibiotics, Cephalosporins antibiotics, and Insulin products. The company was founded on March 6, 2006 and is headquartered in Hong Kong.
|Market Price at 22-11-2017||$6.55|
|Price to Earnings Ratio||-27.6|
|Market Capitalisation||$10,656.06 (million)|
|Return on Equity (ROE)||-5.21%|